生存期-话题@MedSci

#生存期#

350篇内容 | 3607人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1378109, encodeId=25cf13e8109d1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=《卫报》：常见癌症的生存期可延长至10年（皮肤癌，乳腺癌，前列腺癌……）, objectType=article, longId=79270, objectId=00b0e92708f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00b0e92708f, replyNumber=0, likeNumber=86, createdTime=2016-10-07, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00b0e92708f, moduleTitle=《卫报》：常见癌症的生存期可延长至10年（皮肤癌，乳腺癌，前列腺癌……）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00b0e92708f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378108, encodeId=b0dc13e810803, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=常见癌症的生存期可延长至10年（皮肤癌，乳腺癌，前列腺癌……）, objectType=article, longId=79263, objectId=899ee92632c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=899ee92632c, replyNumber=0, likeNumber=91, createdTime=2016-10-07, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=899ee92632c, moduleTitle=常见癌症的生存期可延长至10年（皮肤癌，乳腺癌，前列腺癌……）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=899ee92632c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378107, encodeId=ce0013e8107d5, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=NEJM：利妥昔单抗可延长B细胞急性淋巴细胞白血病患者生存期, objectType=article, longId=77709, objectId=5f4ae770963, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f4ae770963, replyNumber=0, likeNumber=59, createdTime=2016-09-19, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f4ae770963, moduleTitle=NEJM：利妥昔单抗可延长B细胞急性淋巴细胞白血病患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f4ae770963)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378106, encodeId=522013e8106b4, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet：中山大学张力教授证实吉西他滨联合顺铂可延长晚期鼻咽癌患者的无进展生存期, objectType=article, longId=75834, objectId=2e28e58346e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e28e58346e, replyNumber=0, likeNumber=25, createdTime=2016-08-26, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e28e58346e, moduleTitle=Lancet：中山大学张力教授证实吉西他滨联合顺铂可延长晚期鼻咽癌患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e28e58346e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378105, encodeId=a98c13e8105cc, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JCO：额外的伊匹单抗+化疗vs.单独化疗未能延长广泛性SCLC患者生存期(III期试验), objectType=article, longId=74272, objectId=147de42721f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=147de42721f, replyNumber=0, likeNumber=63, createdTime=2016-08-03, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=147de42721f, moduleTitle=JCO：额外的伊匹单抗+化疗vs.单独化疗未能延长广泛性SCLC患者生存期(III期试验), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=147de42721f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378104, encodeId=893513e810444, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=ESMO 2016：Regorafenib显著提高肝细胞癌患者生存期（附梅斯医学评论）, objectType=article, longId=71988, objectId=af3be19889a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af3be19889a, replyNumber=0, likeNumber=70, createdTime=2016-07-03, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af3be19889a, moduleTitle=ESMO 2016：Regorafenib显著提高肝细胞癌患者生存期（附梅斯医学评论）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af3be19889a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378103, encodeId=e5be13e810302, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JCO：血浆维生素D水平能预测胰腺癌患者的总生存期, objectType=article, longId=71796, objectId=1c14e1796aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c14e1796aa, replyNumber=0, likeNumber=26, createdTime=2016-06-30, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c14e1796aa, moduleTitle=JCO：血浆维生素D水平能预测胰腺癌患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c14e1796aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378102, encodeId=676d13e810255, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=默沙东PD-1免疫疗法Keytruda一线治疗晚期非小细胞肺癌（NSCLC）显著延长总生存期和无进展生存期, objectType=article, longId=71400, objectId=0e3be140052, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e3be140052, replyNumber=0, likeNumber=94, createdTime=2016-06-23, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e3be140052, moduleTitle=默沙东PD-1免疫疗法Keytruda一线治疗晚期非小细胞肺癌（NSCLC）显著延长总生存期和无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e3be140052)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378101, encodeId=718313e810176, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=同样的组织病理，为什么生存期大不相同？, objectType=article, longId=71300, objectId=0a81e130066, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a81e130066, replyNumber=0, likeNumber=87, createdTime=2016-06-22, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a81e130066, moduleTitle=同样的组织病理，为什么生存期大不相同？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a81e130066)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378100, encodeId=00a213e81004d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=ASCO 2016：解读左右结直肠癌生存期差异很大, objectType=article, longId=71272, objectId=63b9e1272c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63b9e1272c8, replyNumber=0, likeNumber=74, createdTime=2016-06-22, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63b9e1272c8, moduleTitle=ASCO 2016：解读左右结直肠癌生存期差异很大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63b9e1272c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378099, encodeId=2d8013e809912, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Nat Commun：通过基因异构体比率预测癌症病人生存期更有效, objectType=article, longId=70789, objectId=e177e078989, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e177e078989, replyNumber=0, likeNumber=74, createdTime=2016-06-16, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e177e078989, moduleTitle=Nat Commun：通过基因异构体比率预测癌症病人生存期更有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e177e078989)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378098, encodeId=faec13e8098d2, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=EHA 2016：强生多发性骨髓瘤药物Darzalex+来那度胺+地塞米松三联疗法III期临床显著延长无进展生存期, objectType=article, longId=70647, objectId=2a45e0647b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a45e0647b2, replyNumber=0, likeNumber=76, createdTime=2016-06-15, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a45e0647b2, moduleTitle=EHA 2016：强生多发性骨髓瘤药物Darzalex+来那度胺+地塞米松三联疗法III期临床显著延长无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a45e0647b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378097, encodeId=43cb13e8097c5, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet：olaratumab联合阿霉素可显著改善晚期或转移性软组织肉瘤患者的无进展生存期, objectType=article, longId=70568, objectId=b217e05681b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b217e05681b, replyNumber=0, likeNumber=76, createdTime=2016-06-14, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b217e05681b, moduleTitle=Lancet：olaratumab联合阿霉素可显著改善晚期或转移性软组织肉瘤患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b217e05681b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378096, encodeId=e76313e809699, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Am J Respir Crit Care Med：新的研究发现或可延长囊性纤维化患者的生存期, objectType=article, longId=68206, objectId=44e0682065f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44e0682065f, replyNumber=0, likeNumber=75, createdTime=2016-05-16, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44e0682065f, moduleTitle=Am J Respir Crit Care Med：新的研究发现或可延长囊性纤维化患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44e0682065f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378095, encodeId=cfae13e80955d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=J Clin Sleep Med：打鼾睡眠不足可降低乳腺癌患者的生存期, objectType=article, longId=67934, objectId=c0826e93471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0826e93471, replyNumber=0, likeNumber=63, createdTime=2016-05-12, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0826e93471, moduleTitle=J Clin Sleep Med：打鼾睡眠不足可降低乳腺癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0826e93471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378094, encodeId=ebd913e80947a, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=NEJM：口服Ixazomib、来那度胺、地塞米松治疗可显著延长多发性骨髓瘤患者的无进展生存期（TOURMALINE-MM1研究）, objectType=article, longId=67240, objectId=9d3e6e240f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d3e6e240f2, replyNumber=0, likeNumber=73, createdTime=2016-04-29, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d3e6e240f2, moduleTitle=NEJM：口服Ixazomib、来那度胺、地塞米松治疗可显著延长多发性骨髓瘤患者的无进展生存期（TOURMALINE-MM1研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d3e6e240f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378093, encodeId=6ce713e809338, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Cancer：多个研究发现结婚可延长癌症患者的生存期, objectType=article, longId=66433, objectId=c3dd66433ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3dd66433ca, replyNumber=0, likeNumber=62, createdTime=2016-04-14, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3dd66433ca, moduleTitle=Cancer：多个研究发现结婚可延长癌症患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3dd66433ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378092, encodeId=34b313e80920a, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet：eribulin可显著晚期软组织肉瘤患者总生存期, objectType=article, longId=63154, objectId=eb0463154a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb0463154a9, replyNumber=0, likeNumber=65, createdTime=2016-02-13, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb0463154a9, moduleTitle=Lancet：eribulin可显著晚期软组织肉瘤患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb0463154a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378091, encodeId=058413e809100, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Gastroenterology：强化肠内营养并不能改善重型酒精性肝炎患者生存期, objectType=article, longId=62676, objectId=11ca626e633, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11ca626e633, replyNumber=0, likeNumber=163, createdTime=2016-01-28, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11ca626e633, moduleTitle=Gastroenterology：强化肠内营养并不能改善重型酒精性肝炎患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11ca626e633)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378090, encodeId=faba13e80904f, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet：恶性胸膜间皮瘤——贝伐单抗可显著改善总生存期, objectType=article, longId=60984, objectId=7d006098472, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d006098472, replyNumber=0, likeNumber=71, createdTime=2015-12-23, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d006098472, moduleTitle=Lancet：恶性胸膜间皮瘤——贝伐单抗可显著改善总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d006098472)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

生存期

2020-05-29

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

《卫报》：常见癌症的生存期可延长至10年（皮肤癌，乳腺癌，前列腺癌……）

2016-10-07

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

常见癌症的生存期可延长至10年（皮肤癌，乳腺癌，前列腺癌……）

2016-10-07

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

NEJM：利妥昔单抗可延长B细胞急性淋巴细胞白血病患者生存期

2016-09-19

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

Lancet：中山大学张力教授证实吉西他滨联合顺铂可延长晚期鼻咽癌患者的无进展生存期

2016-08-26

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

JCO：额外的伊匹单抗+化疗vs.单独化疗未能延长广泛性SCLC患者生存期(III期试验)

2016-08-03

智慧医人 (审核中...)

前往app查看评论内容

#生存期#

ESMO 2016：Regorafenib显著提高肝细胞癌患者生存期（附梅斯医学评论）

2016-07-03

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

JCO：血浆维生素D水平能预测胰腺癌患者的总生存期

2016-06-30

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

默沙东PD-1免疫疗法Keytruda一线治疗晚期非小细胞肺癌（NSCLC）显著延长总生存期和无进展生存期

2016-06-23

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

同样的组织病理，为什么生存期大不相同？

2016-06-22

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

ASCO 2016：解读左右结直肠癌生存期差异很大

2016-06-22

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Nat Commun：通过基因异构体比率预测癌症病人生存期更有效

2016-06-16

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

EHA 2016：强生多发性骨髓瘤药物Darzalex+来那度胺+地塞米松三联疗法III期临床显著延长无进展生存期

2016-06-15

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Lancet：olaratumab联合阿霉素可显著改善晚期或转移性软组织肉瘤患者的无进展生存期

2016-06-14

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Am J Respir Crit Care Med：新的研究发现或可延长囊性纤维化患者的生存期

2016-05-16

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

J Clin Sleep Med：打鼾睡眠不足可降低乳腺癌患者的生存期

2016-05-12

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

NEJM：口服Ixazomib、来那度胺、地塞米松治疗可显著延长多发性骨髓瘤患者的无进展生存期（TOURMALINE-MM1研究）

2016-04-29

hb2008ye (审核中...)

前往app查看评论内容

#生存期#

Cancer：多个研究发现结婚可延长癌症患者的生存期

2016-04-14

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Lancet：eribulin可显著晚期软组织肉瘤患者总生存期

2016-02-13

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Gastroenterology：强化肠内营养并不能改善重型酒精性肝炎患者生存期

2016-01-28

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Lancet：恶性胸膜间皮瘤——贝伐单抗可显著改善总生存期

2015-12-23

科室
- - 订阅+
  - 更多科室
工具
服务